Angiogenex Inc (AGGX) financial statements (2020 and earlier)

Company profile

Business Address 425 MADISON AVENUE, SUITE 902
NEW YORK, NY 10017
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments979520117251381494
Cash and cash equivalents979520117251381494
Prepaid expense1524333141322
Total current assets:11212053149255394515
Noncurrent Assets
TOTAL ASSETS:11212053149255394515
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:343295320460437442384
Accrued liabilities203155180621515 
Employee-related liabilities959595959595 
Interest and dividends payable45454545454551
Other undisclosed accounts payable and accrued liabilities   258282287333
Debt125129129129129139139
Due to related parties157172160145180180 
Other undisclosed current liabilities590554488381398452620
Total current liabilities:1,2151,1501,0961,1151,1441,2121,142
Noncurrent Liabilities
Liabilities, other than long-term debt27272727272727
Due to related parties27272727272727
Total noncurrent liabilities:27272727272727
Total liabilities:1,2421,1771,1241,1421,1711,2401,170
Stockholders' equity
Stockholders' equity attributable to parent, including:(1,130)(1,058)(1,071)(993)(916)(846)(655)
Common stock30302929292929
Additional paid in capital6,5776,5035,9125,9035,9005,8825,892
Accumulated deficit(7,738)(7,591)(7,012)(6,926)(6,845)(6,757)(6,576)
Other undisclosed stockholders' equity attributable to parent1      
Total stockholders' equity:(1,130)(1,058)(1,071)(993)(916)(846)(655)
Other undisclosed liabilities and equity     (90) 
TOTAL LIABILITIES AND EQUITY:11212053149255304515

Income statement (P&L) ($ in thousands)

6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
Operating expenses(145)(577)(95)(78)(89)(178)(35)
Other operating income (expense), net
(Other Expenses)
(2)(2)(2)(2)2328
Other undisclosed operating income (loss)22(7)20(3)(28)
Operating loss:(145)(577)(104)(78)(87)(178)(35)
Interest and debt expense22222328
Loss from continuing operations before income taxes:(143)(574)(101)(76)(85)(175)(8)
Other undisclosed loss from continuing operations  (11)    
Net loss:(143)(574)(112)(76)(85)(175)(8)
Other undisclosed net income (loss) attributable to parent(4)(5)27(5)(4)(6)(56)
Net loss available to common stockholders, diluted:(147)(579)(86)(81)(88)(181)(63)

Comprehensive Income ($ in thousands)

6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
Net loss:(143)(574)(112)(76)(85)(175)(8)
Comprehensive loss, net of tax, attributable to parent:(143)(574)(112)(76)(85)(175)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: